Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

25 May 2022

Abstract excerpt

Lung cancer is the leading cause of cancer-related deaths among men and women worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective therapies for advanced non-small-cell lung cancer (NSCLC) patients harbouring EGFR-activating mutations, but are not curative due to the inevitable emergence of resistances. Recent in vitro studies suggest that resistance to EGFR-TKI may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35681591
DOI: 10.3390/cancers14112613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerPMID 35681591Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Semantic proximity Read ↗

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations.Semantic proximity Read ↗

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Target Therapy in Lung Adenocarcinoma Cell LinesSemantic proximity Read ↗

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.Semantic proximity Read ↗

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Semantic proximity Read ↗

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapiesSemantic proximity Read ↗

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.Semantic proximity Read ↗

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.Semantic proximity Read ↗

A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing dataSemantic proximity Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.